Summarized by Masters of Longevity from Longevity Technology.
Alterity’s Parkinson’s trial coverage previews a clinical study report, highlighting analytical approaches and implications for a planned pivotal trial.
Key Takeaways
- Adjusting for baseline cerebrospinal fluid neurofilament light improved detection of treatment effects in the Phase 2 dataset.
- Quantitative susceptibility mapping did not hit the primary substantia nigra iron endpoint but showed a dentate nucleus iron increase with the higher dose.
- The randomized double-blind placebo-controlled study enrolled 77 adults, reported similar adverse event rates versus placebo, and supported a planned Phase 3 trial.
